Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline M Tanner

Showing results (131-140 of 207) with videos related to

Pageof 21
Sort By:
Drug Safety|May 9, 2003
Benefits and risks of pharmacological treatments for essential tremorKelly E Lyons, Rajesh Pahwa, Cynthia L Comella, et al.
Annals of Neurology|November 16, 2011
Solvent exposures and Parkinson disease risk in twinsSamuel M Goldman, Patricia J Quinlan, G Webster Ross, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 17, 2008
Research priorities in spasmodic dysphoniaChristy L Ludlow, Charles H Adler, Gerald S Berke, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 8, 2013
Which dyskinesia scale best detects treatment response?Christopher G Goetz, Glenn T Stebbins, Kathryn A Chung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2017
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trialsAlberto J Espay, Michael A Schwarzschild, Caroline M Tanner, et al.
Environment International|December 3, 2014
Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's diseaseMelissa Furlong, Caroline M Tanner, Samuel M Goldman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 5, 2007
Potential outcome measures and trial design issues for multiple system atrophySusanne May, Sid Gilman, B Brooke Sowell, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2012
Genetic modification of the association of paraquat and Parkinson's diseaseSamuel M Goldman, Freya Kamel, G Webster Ross, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 19, 2007
G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophyLaurie J Ozelius, Tatiana Foroud, Susanne May, et al.
Pageof 21

Showing results (131-140 of 207) with videos related to

Sort By:
Pageof 21
Drug Safety|May 9, 2003
Benefits and risks of pharmacological treatments for essential tremorKelly E Lyons, Rajesh Pahwa, Cynthia L Comella, et al.
Annals of Neurology|November 16, 2011
Solvent exposures and Parkinson disease risk in twinsSamuel M Goldman, Patricia J Quinlan, G Webster Ross, et al.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 17, 2008
Research priorities in spasmodic dysphoniaChristy L Ludlow, Charles H Adler, Gerald S Berke, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 8, 2013
Which dyskinesia scale best detects treatment response?Christopher G Goetz, Glenn T Stebbins, Kathryn A Chung, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 25, 2017
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trialsAlberto J Espay, Michael A Schwarzschild, Caroline M Tanner, et al.
Environment International|December 3, 2014
Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's diseaseMelissa Furlong, Caroline M Tanner, Samuel M Goldman, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 5, 2007
Potential outcome measures and trial design issues for multiple system atrophySusanne May, Sid Gilman, B Brooke Sowell, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 10, 2012
Genetic modification of the association of paraquat and Parkinson's diseaseSamuel M Goldman, Freya Kamel, G Webster Ross, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 19, 2007
G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophyLaurie J Ozelius, Tatiana Foroud, Susanne May, et al.
Pageof 21